Pankreas kanseri, en \u00f6l\u00fcmc\u00fcl b\u00fcy\u00fck kanser t\u00fcrlerinden biri olarak kabul ediliyor. Bunun en \u00f6nemli nedenlerinden biri, hastal\u0131\u011f\u0131n \u00e7o\u011fu zaman ge\u00e7 fark edilmesi. Pek \u00e7ok hasta, ameliyat \u015fans\u0131n\u0131n azald\u0131\u011f\u0131 ileri bir evrede tan\u0131 al\u0131yor. Bu da sa\u011fkal\u0131m oranlar\u0131n\u0131 ciddi bi\u00e7imde d\u00fc\u015f\u00fcr\u00fcyor.<\/p>\n\n\n\n
Tam da bu nedenle ki\u015fiye \u00f6zel geli\u015ftirilen yeni mRNA a\u015f\u0131s\u0131, bilim d\u00fcnyas\u0131nda b\u00fcy\u00fck ilgi yaratt\u0131. Bu a\u015f\u0131 standart bir \u00fcr\u00fcn de\u011fil. Her hasta i\u00e7in, ameliyatla \u00e7\u0131kar\u0131lan t\u00fcm\u00f6rden elde edilen genetik bilgiler kullan\u0131larak \u00f6zel olarak haz\u0131rlan\u0131yor. Ama\u00e7, ba\u011f\u0131\u015f\u0131kl\u0131k sistemine o ki\u015fiye \u00f6zg\u00fc kanser h\u00fccrelerini tan\u0131tmak ve hastal\u0131k geri d\u00f6nerse v\u00fccudun daha h\u0131zl\u0131 tepki vermesini sa\u011flamak.<\/p>\n\n\n\n 6 YIL SONRA GELEN D\u0130KKAT \u00c7EK\u0130C\u0130 SONU\u00c7<\/strong><\/p>\n\n\n\n Payla\u015f\u0131lan faz 1 sonu\u00e7lar\u0131na g\u00f6re \u00e7al\u0131\u015fmaya, hastal\u0131\u011f\u0131 ameliyat edilebilir a\u015famada olan 16 pankreas kanseri hastas\u0131 dahil edildi. Bu hastalara ameliyat sonras\u0131 ki\u015fiye \u00f6zel\u00a0mRNA a\u015f\u0131s\u0131, imm\u00fcnoterapi ve kemoterapi uyguland\u0131.<\/p>\n\n\n\n A\u015f\u0131dan sonra 8 hastada olumlu ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 g\u00f6r\u00fcld\u00fc. Bu gruptaki 8 hastan\u0131n 7\u2019sinin, ameliyattan 4 ila 6 y\u0131l sonra h\u00e2l\u00e2 hayatta oldu\u011fu a\u00e7\u0131kland\u0131. A\u015f\u0131ya yan\u0131t vermeyen grupta ise yaln\u0131zca 2 hastan\u0131n hayatta kald\u0131\u011f\u0131 belirtildi.<\/p>\n\n\n\n Ara\u015ft\u0131rmac\u0131lar, yakla\u015f\u0131k 6 y\u0131ll\u0131k izlemde ba\u011f\u0131\u015f\u0131kl\u0131k yan\u0131t\u0131 geli\u015ftiren hastalar\u0131n yakla\u015f\u0131k y\u00fczde 90\u2019\u0131n\u0131n ya\u015fam\u0131n\u0131 s\u00fcrd\u00fcrd\u00fc\u011f\u00fcn\u00fc ifade ediyor.\u00a0Pankreas kanseri\u00a0gibi tedavisi son derece zor bir alanda bu sonu\u00e7, olduk\u00e7a g\u00fc\u00e7l\u00fc bir sinyal olarak de\u011ferlendiriliyor.<\/p>\n\n\n\n HER HASTADA AYNI ETK\u0130Y\u0130 G\u00d6STERM\u0130YOR<\/strong><\/p>\n\n\n\n Buna kar\u015f\u0131n uzmanlar, hen\u00fcz \u201cpankreas kanserine \u00e7\u00f6z\u00fcm bulundu\u201d demek i\u00e7in erken oldu\u011fu konusunda uyar\u0131yor. \u00c7\u00fcnk\u00fc a\u015f\u0131 her hastada ayn\u0131 etkiyi g\u00f6stermedi. Ayr\u0131ca \u00e7al\u0131\u015fma, yaln\u0131zca ameliyat edilebilen s\u0131n\u0131rl\u0131 say\u0131daki hastay\u0131 kaps\u0131yor. \u0130leri evre ve yay\u0131lm\u0131\u015f pankreas kanserinde bu yakla\u015f\u0131m\u0131n nas\u0131l sonu\u00e7 verece\u011fi hen\u00fcz bilinmiyor.<\/p>\n\n\n\n Yani tablo umut verici olsa da, bu a\u015famada s\u00f6z konusu tedavi y\u00f6ntemi daha \u00e7ok g\u00fc\u00e7l\u00fc bir ba\u015flang\u0131\u00e7 olarak g\u00f6r\u00fcl\u00fcyor. \u015eimdi as\u0131l beklenti, daha geni\u015f hasta gruplar\u0131nda yap\u0131lacak yeni \u00e7al\u0131\u015fmalar\u0131n benzer sonu\u00e7lar\u0131 do\u011frulay\u0131p do\u011frulamayaca\u011f\u0131n\u0131 g\u00f6rmek.<\/p>\n\n\n\n Bu geli\u015fme, mRNA teknolojisinin yaln\u0131zca salg\u0131n d\u00f6nemindeki a\u015f\u0131larla s\u0131n\u0131rl\u0131 kalmayabilece\u011fini de ortaya koyuyor.\u00a0Bilim\u00a0insanlar\u0131, bu y\u00f6ntemin farkl\u0131 kanser t\u00fcrlerinde de kullan\u0131labilece\u011fini d\u00fc\u015f\u00fcn\u00fcyor. \u00d6zellikle ba\u011f\u0131\u015f\u0131kl\u0131k sisteminin yeniden e\u011fitilmesi fikri, gelece\u011fin kanser tedavileri a\u00e7\u0131s\u0131ndan b\u00fcy\u00fck \u00f6nem ta\u015f\u0131yor.<\/p>\n\n\n\n![\"\"](\"https:\/\/neoberidhaber.kahveciyazilim.com\/wp-content\/uploads\/2026\/04\/69ea09933a5a98d212b0f9b1.webp\")
<\/figure>\n\n\n\n
\n\n\n\n